Skip to content

Magnesium and Rotational Thromboelastometry (ROTEM) in Colorectal Cancer Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01938300
Enrollment
44
Registered
2013-09-10
Start date
2011-06-30
Completion date
2013-10-31
Last updated
2015-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

Magnesium sulphate is given to the patients during the colorectal cancer surgery under the hypothesis that it would attenuate the postoperative hypercoagulability. The investigators intend to characterize the changes of coagulation in colorectal cancer patients by using the point-of-care device after the infusion of magnesium sulphate.

Interventions

DRUGMagnesium Sulfate
DRUGNormal saline

Sponsors

Seoul National University Bundang Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* The patients undergoing a laparoscopic colorectal cancer surgery

Exclusion criteria

* Renal disease * Hepatic disease * Neuromuscular disease * Coagulation disorder * Cardiopulmonary disease

Design outcomes

Primary

MeasureTime frame
Change of MCF of EXTEM1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day
Change of Alpha angle of INTEM1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day
Change of MCF of INTEM1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day
Change of CT of EXTEM1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day
Change of CFT of EXTEM1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day
Change of Alpha angle of EXTEM1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day
Change of maximum clot firmness (MCF) of FIBTEM1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day
Change of Clotting time (CT) of INTEM1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day
Change of Clot firmness time (CFT) of INTEM1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day

Secondary

MeasureTime frame
Change of Hemoglobin1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day
Change of Platelet count1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day
Change of International normalized ratio of prothrombin time1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day
Change of Fibrinogen1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day
Change of Activated partial thrombin time1 day before a operation, 1 hour after finishing a operation, and a postopearative 3 day

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026